Skip to main content

Table 3 Decrease in monthly seizure frequency

From: Clinical evaluation of a combination therapy of imepitoin with phenobarbital in dogs with refractory idiopathic epilepsy

     95% Confidence Interval   % of animals with
Variable Cohort N %Decrease LCL UCL p-value any reduction >50% reduction
MSF A 16 15.46 −67.03 57.22 0.607 50.0 37.5
A* 15* 27.24 −38.96 61.90 0.310 53.3 40.0
B 11 35.73 1.69 57.94 0.043 81.8 36.4
C 7 39.41 −3.77 64.58 0.063 71.4 42.9
A + B 27 26.29 −7.36 49.44 0.180 63.0 37.0
A + B + C 34 27.75 −1.51 48.57 0.060 64.7 38.2
MCD A 16 −16.77 −161.95 47.95 0.688   
A* 15* 4.69 −98.58 54.25 0.890   
B 11 17.88 −46.52 53.98 0.466   
C 7 8.06 −105.03 58.77 0.806   
A + B 27 −1.21 −68.03 −64.05 0.962   
A + B + C 34 0.80 −50.53 34.69 0.969   
  1. MSF = (Number of Seizures/Number of days) x 28 days. MCD = (Number of Cluster days/Number of days) x 28 days. Significant %Decrease (p < 0.05) is bolded. In addition, the paired t-test was applied to the corresponding log-transformed data values separately for each cohort and the two combinations of cohorts (i.e., cohort A + B and all 3 cohorts combined). The displayed p-value is derived from this paired t-test. The fraction of animals showing any reduction and >50% reduction of MSF (“Responder rate”) is given
  2. *excluding animal No. 6 of cohort A as outlier